ACET Insider Trading

Insider Ownership Percentage: 7.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Adicet Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Adicet Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Adicet Bio Share Price & Price History

Current Price: $0.62
Price Change: Price Increase of +0.007 (1.14%)
As of 07/3/2025 04:56 PM ET

This chart shows the closing price history over time for ACET up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AugSepOctNovDecJanFebMarAprMayJun$0.62Closing price on 07/04/25:

SEC Filings (Institutional Ownership Changes) for Adicet Bio (NASDAQ:ACET)

83.89% of Adicet Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ACET by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$199kbought$119ksoldQ3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5M$0$5MTotal InflowsTotal Outflows
Adicet Bio logo
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Read More on Adicet Bio

Today's Range

Now: $0.62
Low: $0.58
High: $0.62

50 Day Range

MA: $0.68
Low: $0.48
High: $0.82

52 Week Range

Now: $0.62
Low: $0.45
High: $1.70

Volume

545,982 shs

Average Volume

655,306 shs

Market Capitalization

$51.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Who are the company insiders with the largest holdings of Adicet Bio?

Adicet Bio's top insider investors include:
  1. Orbimed Advisors Llc (Director)
  2. Chen Schor (CEO)
  3. Michael Kauffman (Director)
Learn More about top insider investors at Adicet Bio.